University of California
Welcome,         Profile    Billing    Logout  
 12 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Mark C
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
02/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
SCALP1, NCT05910450: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

Recruiting
3
726
US, RoW
Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle
Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research
Alopecia, Androgenetic
10/24
04/25
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting
3
693
Europe, Canada, Japan, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
08/25
04/26
NCT05772520: The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

Completed
2
82
US
TLL018 tablets, TLL018 Placeboes
Hangzhou Highlightll Pharmaceutical Co., Ltd
Plaque Psoriasis
12/24
12/24
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Recruiting
2
154
Europe, Canada, US
Oral EP262, Placebo
Escient Pharmaceuticals, Inc
Chronic Spontaneous Urticaria
06/25
07/25
IDAML, NCT01518556: Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia

Active, not recruiting
1/2
49
RoW
Idarubicin, IDARU INJ
Konkuk University Medical Center, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Seoul National University Hospital, Ewha Womans University, Samsung Medical Center, Chonbuk National University Hospital, Pusan National University Hospital, Hanyang University Seoul Hospital, Soon Chun Hyang University
Leukemia, Myeloid, Acute
06/24
06/25
NCT06119529: A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

Terminated
1
18
US
LY3872386, Prednisone, Placebo
Eli Lilly and Company
Healthy, Atopic Dermatitis
04/24
04/24
VA_LCP, NCT04008940: Locking Plates for Distal Femur Fractures - a Multicenter Case Review

Active, not recruiting
N/A
100
Europe, US
Distal femur plates
AO Innovation Translation Center
Distal Femur Fracture
06/25
06/25
Albertson, Timothy
NCT05354141: Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Recruiting
3
970
US
ExoFlo, Intravenous normal saline
Direct Biologics, LLC
Acute Respiratory Distress Syndrome, ARDS
03/25
08/25
I-SPY_COVID, NCT04488081: I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Recruiting
2
1500
US
Remdesivir, GS-5734, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Firazyr, Apremilast, Otezla, dornase alfa, Pulmozyme, Celecoxib, celebrex, Famotidine, Pepcid, IC14, Aviptadil, Zyesami, narsoplimab, OMS721, Cyproheptadine, periactin, Cyclosporine, CsA
QuantumLeap Healthcare Collaborative, University of California, San Francisco, University of Pennsylvania, Emory University, University of Alabama at Birmingham, University of Colorado, Denver, University of Southern California, Yale University, Wake Forest University Health Sciences, Sanford Health, Long Beach Memorial Medical Center, Georgetown University, University of California, Davis, Hoag Memorial Hospital Presbyterian, Main Line Health, DHR Health Institute for Research and Development, University of California, Irvine, Corewell Health, Kaiser Permanente, University of Michigan, West Virginia University, University of Miami, University Hospitals Cleveland Medical Center, Virtua Health, M.D. Anderson Cancer Center
COVID-19
07/28
07/30
NCT05496868 / 2022-001612-25: Add-on Reparixin in Adult Patients With ARDS

Recruiting
2
66
Europe, US
Reparixin 600mg, REP, Matching Placebo, Control
Dompé Farmaceutici S.p.A, Dompè farmaceutici s.p.a.
Acute Respiratory Distress Syndrome, Adult
08/25
08/25
Abouyared, Marianne
NCT04967391: Tumescence in HNC Skin Graft Reconstruction

Recruiting
3
58
US
Tumescence During STSG Harvest
University of California, Davis
Head and Neck Cancer, Surgery--Complications, Graft Failure
12/24
12/24
NCT06722508: Exercise and Nutritional Prehabilitation for Head and Neck Cancer Patients

Recruiting
N/A
20
US
exercise and nutritional prehabilitation
University of California, Davis
Head Cancer, Neck Cancer, Sarcopenia, Head and Neck Cancer
08/25
12/25
Javidan, Yashar
NCT06368245: Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions

Not yet recruiting
N/A
1244
Europe, Canada, Japan, US, RoW
long-segment posterior TL instrumented fusion
AO Foundation, AO Spine
Spinal Fusion
12/27
07/29

Download Options